Not only is steatosis diminished, but the inflammatory and fibrogenic responses are abolished in 5-HT2A-cKO mice upon HFD challenge, suggesting that 5-HT2A antagonists could represent a treatment strategy for steatohepatitis and liver fibrosis 198,277,278. This evidence concerns the gene HTR2A and steatosis.